|Awarded On||August 20, 2014|
|Title||Targeting Hypoxia in Breast Cancer With Highly Potent Small- Molecule Anticancer Prodrugs|
|Award Mechanism||Individual Investigator|
|Principal Investigator/Program Director||Kevin G Pinney|
While a number of new therapies are available to breast cancer patients, all too many will succumb to the disease, particularly for late stage metastatic presentation. Studies have shown increased cancer metastasis and a poor prognosis for individuals whose tumors have regions of low oxygen levels (hypoxia). Tumor hypoxia also represents an opportunity as a target for the selective delivery of anticancer agents. Our ultimate goal is to eliminate the mortality associated with metastatic breast cancer through treatment regimens with drugs that are designed to be non-cytotoxic until they reach hypoxic regions in tumors and become activated as highly potent anticancer agents. Success will lead t...